Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 8, 2007 - Issue 16
Submit an article Journal homepage
96
Views
3
CrossRef citations to date
0
Altmetric
Review

Recent advances in the treatment of hyponatremia

Sabiha M Hussain Division of Nephrology and Hypertension, 4th floor south tower, 320E North Ave, Pittsburgh, PA 15212, USA +1 412 359 3319; +1 412 359 4136; [email protected]
, MD,
Kalathil K Sureshkumar Division of Nephrology and Hypertension, 4th floor south tower, 320E North Ave, Pittsburgh, PA 15212, USA +1 412 359 3319; +1 412 359 4136; [email protected]
&
Richard J Marcus Division of Nephrology and Hypertension, 4th floor south tower, 320E North Ave, Pittsburgh, PA 15212, USA +1 412 359 3319; +1 412 359 4136; [email protected]
Pages 2729-2741 | Published online: 24 Oct 2007

Bibliography

  • ADROGUE HJ, MADIAS NE: Hyponatremia. N. Engl. J. Med. (2000) 342:1581-1589.
  • HAWKINS RC: Age and gender as risk factors for hyponatremia and hypernatremia. Clin. Chim. Acta (2003) 337:169-172.
  • HOORN E, LINDEMANS J, ZIESTE R: Hyponatremia in hospitalized patients: epidemiology, etiology, and symptomatology. American Society of Nephrology. St. louis, MO, USA (2004) (Abstr. 561).
  • DEVITA MV, GARDENSWARTZ MH, KONECKY A, ZABETAKIS PM: Incidence and etiology of hyponatremia in an intensive care unit. Clin. Nephrol. (1990) 34:163-166.
  • MILLER M, MORLEY JE, RUBENSTEIN LZ: Hyponatremia in nursing home population. J. Am. Geriatr. Soc. (1995) 43:1410-1413.
  • UPADHYAY A, JABER BL, MADIAS NE: Incidence and prevalence of hyponatremia. Am. J. Med. (2006) 119(Suppl. 1):S30-S35.
  • ALMOND CS, SHIN AY, FORTESCUE EB et al.: Hyponatremia among runners in the Boston marathon. N. Engl. J. Med. (2005) 352:1550-1556.
  • CHEN MC, CHANG HW, CHENG CI: Risk stratification of in hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology (2003) 100:136-142.
  • BORRONI G, MAGGI A, SANGIOVANNI A et al.: Clinical relevance of hyponatremia for the hospital outcome of cirrhotic patients. Dig. Liver Dis. (2000) 32:605-610.
  • ROSE BD, POST TW: Hypoosmolar state – hyponatremia. In: Clinical Physiology of Acid-base and Electrolyte Disorders (5th Editon). McGraw-Hill (2001):696-746.
  • SHCRIER RW: The syndrome of inappropriate antidiuretic hormone secretion and other hypo-osmolar disorders. In: Diseases of the Kidney and Urinary Tract (7th Edition). Lippincott Williams and Wilkins, Philadelphia, PA (2001):2511-2548.
  • BAYLIS PH: Osmoregulation and control of vasopressin secretion in healthy humans. Am. J. Physiol. (1987) 253:R671-R678.
  • ISHIKAWA SE, SCHRIER RW: Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin. Endocrinol. (2003) 58:1-17.
  • ROBERTSON GL: Physiology of ADH secretion. Kidney Int. Suppl. (1987) 21:S20-S26.
  • THRASHER TN, CHEN HG, KEIL LC: Arterial baroreceptors control plasma vasopressin responses to graded hypotension in conscious dogs. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 278:R469-R475.
  • KAKIYA S, ARIMA H, YOKOI H, MURASE T, YAMBE Y, OISO Y: Effects of acute hypotensive stimuli on arginine vasopressin gene transcription in the rat hypothalamus. Am. J. Physiol. Endocrinol. Metab. (2000) 279:E886-E892.
  • THIBONNIER M, CONARTY DM, PRESTON JA, WILKINS PL, BERTI-MATTERA LN, MATTERA R: Molecular pharmacology of human vasopressin receptors. Adv. Exp. Med. Biol. (1998) 449:251-276.
  • NIELSEN S, KWON TH, CHRISTENSEN BM, PROMENEUR D, FROKIAER J, MARPLES D: Physiology and pathophysiology of renal aquaporins. J. Am. Soc. Nephrol. (1999) 10:647-663.
  • GOLDSMITH SR, FRANCIS GS, COWLEYAW, LEVINE TB, COHN JN: Increased plasma arginine vasopressin level in patients with congestive heart failure. J. Am. Coll. Cardiol. (1983) 1:1388-1390.
  • BICHET D, SZATALOWICZ V, CHAIMOVITZ C, SCHRIER RW: Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann. Intern. Med. (1982) 96:413-417.
  • BAYLIS PH: The syndrome of inappropriate antidiuretic hormone secretion. Int. J. Biochem. Cell. Biol. (2003) 35:1495-1499.
  • Ellison DH, BERL T: The syndrome of inappropriate antidiuresis. N. Engl. J. Med. (2007) 356:2064-2072.
  • RENNEBOOG B, VENDEMERGEL X, MANTO MU, DECAUX G: Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. Am. J. Med. (2006) 119:E1-E8.
  • DOUGLAS I: Hyponatremia: why it matters, how it presents, how we can manage it. Clev. Clin. J. Med. (2006) 73:S4-S12.
  • JANICIC N, VERBALIS JG: Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol. Metab. Clin. North Am. (2003) 32:459-481.
  • HILLIER TA, ABOTT RD, BARRETT EJ: Hyponatremia: evaluating the correction factor for hyperglycemia. Am. J. Med. (1999) 106:399-403.
  • TURCHIN A, SEIFTER JL, SEELY EW: Mind the gap. N. Eng. J. Med. (2003) 349:1465-1469.
  • LAURENO R, KARP BI: Myelinolysis after correction of hyponatremia. Ann. Intern. Med. (1997) 126:57-62.
  • COSTELLO-BOERRIGTER LC, BOERRIGTER G, BURNETT JC Jr: Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med. Clin. North Am. (2003) 87:475-491.
  • VERBALIS JG: Vasopressin V2 receptor antagonists. J. Mol. Endocrinol. (2002) 29:1-9.
  • THIBONNIER M, COLES P, THIBONNIER A, SHOHAM M: The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu. Rev. Pharmacol. Toxicol. (2001) 41:175-202.
  • MACION-DAZARD R, CALLAHAN N, XU Z, WU N, THIBONNIER M, SHOHAM M: Mapping the binding site of six nonpeptide antagonists to the human V2- renal vasopressin receptor. J. Pharmacol. Exp. Ther. (2006) 316:564-571.
  • UDELSON JE, SMITH WB, HENDRIX GH et al.: Acute hemodynamic effects of conivaptan, a dual V (1A) and V (2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation (2001) 104:2417-2423.
  • VERBALIS JG, BISAHA JG, SMITH N: Novel vasopressin V1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia: J. Card. Fail. (2004) 10:S27 (Abstr. 036).
  • GHALI JK, KOREN MJ, TAYLOR JR et al.: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonists, assessed in a randomized, placebo controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. (2006) 91:2145-2152.
  • GHEORGHIADE M, NIAZI I, OUYANG J et al.: Vasopressin V2-Receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107:2690-2696.
  • GHEORGHIADE M, GATTIS WA, O'CONNOR CM et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 291:1963-1971.
  • GHEORGHIADE M, GOTTLIEB SS, UDELSON JE et al.: Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol. (2006) 97:1064-1067.
  • SCHRIER RW, GROSS P, GHEORGHIADE M et al.: Tolvaptan, a selective oral vasopressin V2 receptor antagonist, for hyponatremia. N. Engl. J. Med. (2006) 355:2099-2112.
  • WONG F, BLEI AT, BLENDIS LM, THULUVATH PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized placebo controlled trial. Hepatology (2003) 37:182-191.
  • GERBES AL, GULBERG V, GINES P et al.: therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double blind multicenter trial. Gastroenterology (2003) 124:933-939.
  • SOUPART A, GROSS P, LEGROS J et al.: Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan, an orally active nonpeptide vasopressin V2-receptor antagonist. Clin. J. Am. Nehrol. (2006) 1:1154-1160.
  • DECAUX G, SOUPART A: Treatment of symptomatic hyponatremia. Am. J. Med. Sci. (2003) 326:25-30.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.